FI118511B - Pienten partikkelien muodostuminen - Google Patents

Pienten partikkelien muodostuminen Download PDF

Info

Publication number
FI118511B
FI118511B FI971947A FI971947A FI118511B FI 118511 B FI118511 B FI 118511B FI 971947 A FI971947 A FI 971947A FI 971947 A FI971947 A FI 971947A FI 118511 B FI118511 B FI 118511B
Authority
FI
Finland
Prior art keywords
polymer
att
solvent
kännetecknat
och
Prior art date
Application number
FI971947A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI971947A (fi
FI971947A0 (fi
Inventor
Sylvan Frank
Jan-Erik Loefroth
Levon Bostanian
Original Assignee
Univ Ohio State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ohio State Res Found filed Critical Univ Ohio State Res Found
Publication of FI971947A publication Critical patent/FI971947A/fi
Publication of FI971947A0 publication Critical patent/FI971947A0/fi
Application granted granted Critical
Publication of FI118511B publication Critical patent/FI118511B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/06—Making microcapsules or microballoons by phase separation
    • B01J13/10—Complex coacervation, i.e. interaction of oppositely charged particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Surgical Instruments (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Confectionery (AREA)
  • Soft Magnetic Materials (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
FI971947A 1994-11-09 1997-05-07 Pienten partikkelien muodostuminen FI118511B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9403846 1994-11-09
SE9403846A SE9403846D0 (sv) 1994-11-09 1994-11-09 Small particle formation
PCT/SE1995/001302 WO1996014833A1 (en) 1994-11-09 1995-11-03 Small particle formation
SE9501302 1995-11-03

Publications (3)

Publication Number Publication Date
FI971947A FI971947A (fi) 1997-05-07
FI971947A0 FI971947A0 (fi) 1997-05-07
FI118511B true FI118511B (fi) 2007-12-14

Family

ID=20395907

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971947A FI118511B (fi) 1994-11-09 1997-05-07 Pienten partikkelien muodostuminen

Country Status (27)

Country Link
US (1) US5780062A (de)
EP (1) EP0788350B1 (de)
JP (1) JP4098827B2 (de)
KR (1) KR970706799A (de)
CN (1) CN1165478A (de)
AT (1) ATE213625T1 (de)
AU (1) AU700644B2 (de)
BR (1) BR9509720A (de)
CA (1) CA2203512A1 (de)
CZ (1) CZ129597A3 (de)
DE (1) DE69525639T2 (de)
DK (1) DK0788350T3 (de)
EE (1) EE9700214A (de)
ES (1) ES2173204T3 (de)
FI (1) FI118511B (de)
HU (1) HUT77629A (de)
IL (1) IL115878A0 (de)
IS (1) IS4467A (de)
NO (1) NO971986D0 (de)
NZ (1) NZ295497A (de)
PL (1) PL320425A1 (de)
PT (1) PT788350E (de)
SE (1) SE9403846D0 (de)
SK (1) SK55997A3 (de)
TR (1) TR199501400A2 (de)
WO (1) WO1996014833A1 (de)
ZA (1) ZA959386B (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US7029700B2 (en) * 2000-01-14 2006-04-18 Brown University Research Foundation Micronized freeze-dried particles
WO2001052818A1 (en) 2000-01-19 2001-07-26 Pharmaceutical Discovery Corporation Dry powder formulations of antihistamine for nasal administration
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6623761B2 (en) 2000-12-22 2003-09-23 Hassan Emadeldin M. Method of making nanoparticles of substantially water insoluble materials
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
WO2002055059A2 (en) * 2000-12-22 2002-07-18 Baxter Int Method for preparing submicron particle suspensions
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6607784B2 (en) * 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
DE10117049A1 (de) * 2001-04-05 2002-10-17 Novartis Ag Zusammensetzung
WO2003000226A2 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
ATE365537T1 (de) * 2001-08-06 2007-07-15 Astrazeneca Ab Wässrige dispersion stabiler nanopartikel eines wasserunlöslichen wirkstoffs und ein hilfsstoff wie mittelkettige triglyceride (mct)
EP1423175B1 (de) * 2001-08-08 2013-10-02 Brown University Research Foundation Verfahren zur mikronisierung von hydrophoben arzneistoffen
EP1429749A2 (de) 2001-09-26 2004-06-23 Baxter International Inc. Herstellung von nanopartikeln im submikrometerbereich durch dispersion und entzug des lösungsmittels oder der flüssigen phase
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
US20040028747A1 (en) * 2002-08-06 2004-02-12 Tucker Christopher J. Crystalline drug particles prepared using a controlled precipitation process
GB0230087D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0230088D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302673D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7511079B2 (en) * 2003-03-24 2009-03-31 Baxter International Inc. Methods and apparatuses for the comminution and stabilization of small particles
WO2004103348A2 (en) * 2003-05-19 2004-12-02 Baxter International Inc. Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers
GB0314057D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
US20060135523A1 (en) * 2003-06-18 2006-06-22 Astrazeneca Ab 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator
GB0314261D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
US8986736B2 (en) * 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
BRPI0414970A2 (pt) * 2003-06-24 2012-12-11 Baxter Int método para transporte de drogas ao cérebro
SG135189A1 (en) 2003-09-22 2007-09-28 Baxter Int High-pressure sterilization to terminally sterilize pharmaceutical preparations and medical products
WO2005032511A2 (en) * 2003-09-30 2005-04-14 Spherics, Inc. Nanoparticulate therapeutic biologically active agents
DE10351087A1 (de) * 2003-10-31 2005-05-25 Bayer Technology Services Gmbh Feste Wirkstoff-Formulierung
AU2005209243A1 (en) * 2004-01-29 2005-08-11 Baxter Healthcare S.A. Nanosuspensions of anti-retroviral agents for increased central nervous system delivery
WO2005077337A2 (en) * 2004-02-05 2005-08-25 Baxter International Inc. Dispersions prepared by use of self-stabilizing agents
CN101310011A (zh) * 2004-06-15 2008-11-19 巴克斯特国际公司 固相微颗粒治疗剂的离体应用
US20080171687A1 (en) * 2004-09-16 2008-07-17 Abraxis Bioscience, Inc. Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs
WO2008135855A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
WO2008135828A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
EP2152274A4 (de) * 2007-05-07 2010-07-21 Questor Pharmaceuticals Inc Nasale verabreichung von benzodiazepinen
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
EP2162120B1 (de) 2007-06-04 2016-05-04 Bend Research, Inc Nanopartikel mit nicht ionisierbarem zellulosepolymer und amphipilem nicht ionisierbarem blockcopolymer
US8101274B2 (en) * 2007-06-11 2012-01-24 Spedden Richard H Solid state membranes with surface-embedded glycosylated amphiphilic molecules and micelles formed therefrom
GB0714223D0 (en) * 2007-07-20 2007-08-29 Fujifilm Mfg Europe Bv Preparation of fine particles
EP2231169B1 (de) 2007-12-06 2016-05-04 Bend Research, Inc. Pharmazeutische zusammensetzungen mit nanopartikeln und resuspensionsmaterial
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
EP2259798B1 (de) 2008-03-05 2013-12-11 Baxter International Inc. Zusammensetzungen und verfahren zur wirkstofffreisetzung
EP2271347B1 (de) * 2008-03-28 2016-05-11 Hale Biopharma Ventures, Llc Verabreichung von benzodiazepin-zusammensetzungen
CN101278921B (zh) * 2008-06-03 2010-06-09 海南百那医药发展有限公司 盐酸托烷司琼微囊及其注射剂生产方法
US20100151037A1 (en) * 2008-08-07 2010-06-17 Yivan Jiang Method for the preparation of nanoparticles containing a poorly water-soluble pharmaceutically active compound
KR20110042107A (ko) 2008-08-07 2011-04-22 바이오엑티브 써지컬, 아이엔씨. 의료 장치 및 이식물을 위한 줄기 세포 포획 및 고정화 코팅
US10952965B2 (en) * 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
CN102784103A (zh) * 2011-05-16 2012-11-21 中国科学院上海药物研究所 一种通过混合胶束技术制备的普罗布考纳米混悬液及其制备方法
US20140199397A1 (en) * 2011-06-10 2014-07-17 Daniel Levin Benzoyl Peroxide Microparticle Process
EP2720699B1 (de) 2011-06-14 2018-05-16 Hale Biopharma Ventures, Llc Verabreichung von benzodiazepin
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2016181406A1 (en) * 2015-05-08 2016-11-17 Davuluri Ramamohan Rao Improved process for the preparation of aripiprazole with reduced particle size

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
CA1282405C (en) * 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4606940A (en) * 1984-12-21 1986-08-19 The Ohio State University Research Foundation Small particle formation and encapsulation
JPH0249720A (ja) * 1988-05-18 1990-02-20 Mitsubishi Kasei Corp 難溶性薬剤組成物
SE464743B (sv) * 1989-06-21 1991-06-10 Ytkemiska Inst Foerfarande foer framstaellning av laekemedelspartiklar
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.

Also Published As

Publication number Publication date
CA2203512A1 (en) 1996-05-23
NZ295497A (en) 1998-05-27
AU3885195A (en) 1996-06-06
US5780062A (en) 1998-07-14
KR970706799A (ko) 1997-12-01
DE69525639D1 (de) 2002-04-04
CZ129597A3 (en) 1997-12-17
HUT77629A (hu) 1998-06-29
JPH10508840A (ja) 1998-09-02
SK55997A3 (en) 1998-01-14
BR9509720A (pt) 1997-10-21
NO971986L (no) 1997-04-29
ZA959386B (en) 1996-05-09
EP0788350B1 (de) 2002-02-27
ES2173204T3 (es) 2002-10-16
FI971947A (fi) 1997-05-07
PL320425A1 (en) 1997-09-29
JP4098827B2 (ja) 2008-06-11
AU700644B2 (en) 1999-01-14
CN1165478A (zh) 1997-11-19
DE69525639T2 (de) 2002-08-29
ATE213625T1 (de) 2002-03-15
PT788350E (pt) 2002-07-31
SE9403846D0 (sv) 1994-11-09
EP0788350A1 (de) 1997-08-13
IL115878A0 (en) 1996-01-31
EE9700214A (et) 1998-04-15
IS4467A (is) 1997-04-21
FI971947A0 (fi) 1997-05-07
WO1996014833A1 (en) 1996-05-23
TR199501400A2 (tr) 1996-06-21
NO971986D0 (no) 1997-04-29
DK0788350T3 (da) 2002-04-29

Similar Documents

Publication Publication Date Title
FI118511B (fi) Pienten partikkelien muodostuminen
Qin et al. Supra-amphiphilic aggregates formed by p-sulfonatocalix [4] arenes and the antipsychotic drug chlorpromazine
Wang et al. Stability of nanosuspensions in drug delivery
Nesamony et al. Calcium alginate nanoparticles synthesized through a novel interfacial cross-linking method as a potential protein drug delivery system
Riley et al. Colloidal stability and drug incorporation aspects of micellar-like PLA–PEG nanoparticles
Radowski et al. Supramolecular aggregates of dendritic multishell architectures as universal nanocarriers
EP0363549B1 (de) Verfahren zur Herstellung eines wasserlöslichen Polymerpulvers, das in einer flüssigen Phase redispergiert werden kann und Verfahren zur Herstellung einer Dispersion des Polymerpulvers
EP0700679B1 (de) Injizierbare liposomale Arzneizubereitungen
Bharmoria et al. Complexation of chitosan with surfactant like ionic liquids: Molecular interactions and preparation of chitosan nanoparticles
JP2003521508A (ja) リポソーム
KR20180025318A (ko) 친유성 화합물 전달용 나노캡슐 및 그 제조 방법
CA2442539A1 (en) Method and composition for solubilising a biologically active compound with low water solubility
JPH09501101A (ja) 液滴またはナノメータ粒子の被覆方法
Chen et al. Protein/surfactant interfacial interactions paet 2. Electrophoretic mobility of mixed protein+ surfactant systems
Hu et al. Polymersomes: Preparation and characterization
Péroche et al. Synthesis and characterisation of novel nanospheres made from amphiphilic perfluoroalkylthio-β-cyclodextrins
Helttunen et al. Solid lipid nanoparticles from amphiphilic calixpyrroles
Kumar et al. A Review on Lyotropic Liquid Crystals and Its Potential Applications
Hasan et al. Novel castor oil/water/ethanol Pickering emulsions stabilized by magnetic nanoparticles and magnetically controllable demulsification
CA2460649A1 (en) Novel calixarene based dispersible colloidal systems in the form of nanoparticles
JP4669665B2 (ja) 細胞毒性のないポリカチオン修飾リポソームおよびその製造方法
Sahib et al. Preparation and in-vitro hematological evaluation of chlorambucil loaded lipid nanoparticles
Haso et al. Solution behaviour of a polymer with polyoxometalate inorganic molecular clusters in its main chain
Chopra et al. Formulation, characterization and in vivo evaluation of self-nanoemulsifying drug delivery system for oral delivery of valsartan
Monnier et al. A guide to investigating colloidal nanoparticles by cryogenic transmission electron microscopy: pitfalls and benefits

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 118511

Country of ref document: FI

MM Patent lapsed